Wang Xuan, Hua Peng, He Chengwei, Chen Meiwan
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, SAR 999078, China.
Acta Pharm Sin B. 2022 Sep;12(9):3567-3593. doi: 10.1016/j.apsb.2022.03.020. Epub 2022 Apr 1.
As an emerging cancer therapeutic target, non-apoptotic cell death such as ferroptosis, necroptosis and pyroptosis, etc., has revealed significant potential in cancer treatment for bypassing apoptosis to enhance the undermined therapeutic efficacy triggered by apoptosis resistance. A variety of anticancer drugs, synthesized compounds and natural products have been proven recently to induce non-apoptotic cell death and exhibit excellent anti-tumor effects. Moreover, the convergence of nanotechnology with functional materials and biomedicine science has provided tremendous opportunities to construct non-apoptotic cell death-based nanomedicine for innovative cancer therapy. Nanocarriers are not only employed in targeted delivery of non-apoptotic inducers, but also used as therapeutic components to induce non-apoptotic cell death to achieve efficient tumor treatment. This review first introduces the main characteristics, the mechanism and various pharmacological modulators of different non-apoptotic cell death forms, including ferroptosis, necroptosis, pyroptosis, autophagy, paraptosis, lysosomal-dependent cell death, and oncosis. Second, we comprehensively review the latest progresses of nanomedicine that induces various forms of non-apoptotic cell death and focus on the nanomedicine targeting different pathways and components. Furthermore, the combination therapies of non-apoptotic cell death with photothermal therapy, photodynamic therapy, immunotherapy and other modalities are summarized. Finally, the challenges and future perspectives in this regard are also discussed.
作为一种新兴的癌症治疗靶点,铁死亡、坏死性凋亡和焦亡等非凋亡性细胞死亡在癌症治疗中已显示出巨大潜力,可绕过凋亡以增强由凋亡抗性引发的治疗效果不佳的情况。最近已证实,多种抗癌药物、合成化合物和天然产物可诱导非凋亡性细胞死亡并展现出优异的抗肿瘤效果。此外,纳米技术与功能材料及生物医学科学的融合为构建基于非凋亡性细胞死亡的纳米药物用于创新癌症治疗提供了巨大机遇。纳米载体不仅用于非凋亡诱导剂的靶向递送,还用作治疗成分来诱导非凋亡性细胞死亡以实现高效肿瘤治疗。本综述首先介绍不同非凋亡性细胞死亡形式(包括铁死亡、坏死性凋亡、焦亡、自噬、副凋亡、溶酶体依赖性细胞死亡和胀亡)的主要特征、机制及各种药理学调节剂。其次,我们全面综述诱导各种形式非凋亡性细胞死亡的纳米药物的最新进展,并聚焦于靶向不同途径和成分的纳米药物。此外,还总结了非凋亡性细胞死亡与光热疗法、光动力疗法、免疫疗法及其他疗法的联合治疗。最后,也讨论了这方面的挑战和未来展望。